JP2023526890A5 - - Google Patents

Info

Publication number
JP2023526890A5
JP2023526890A5 JP2022560455A JP2022560455A JP2023526890A5 JP 2023526890 A5 JP2023526890 A5 JP 2023526890A5 JP 2022560455 A JP2022560455 A JP 2022560455A JP 2022560455 A JP2022560455 A JP 2022560455A JP 2023526890 A5 JP2023526890 A5 JP 2023526890A5
Authority
JP
Japan
Prior art keywords
antibody
seq
pharmaceutical composition
nos
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526890A (ja
Filing date
Publication date
Priority claimed from CU2020000027A external-priority patent/CU20200027A7/es
Application filed filed Critical
Priority claimed from PCT/IB2021/052793 external-priority patent/WO2021199006A1/en
Publication of JP2023526890A publication Critical patent/JP2023526890A/ja
Publication of JP2023526890A5 publication Critical patent/JP2023526890A5/ja
Pending legal-status Critical Current

Links

JP2022560455A 2020-04-04 2021-04-03 Covid-19を包含するコロナウイルスの負の効果を処置および低減をするための抗cd6抗体組成物および方法 Pending JP2023526890A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN202041014994 2020-04-04
IN202041014994 2020-04-04
CU2020000027A CU20200027A7 (es) 2020-04-17 2020-04-17 Uso de anticuerpos monoclonales anti-cd6 no depletantes en el tratamiento de la tormenta de citocinas
CUCU-2020-0027 2020-04-17
PCT/IB2021/052793 WO2021199006A1 (en) 2020-04-04 2021-04-03 Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19

Publications (2)

Publication Number Publication Date
JP2023526890A JP2023526890A (ja) 2023-06-26
JP2023526890A5 true JP2023526890A5 (cg-RX-API-DMAC7.html) 2024-04-12

Family

ID=77928142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560455A Pending JP2023526890A (ja) 2020-04-04 2021-04-03 Covid-19を包含するコロナウイルスの負の効果を処置および低減をするための抗cd6抗体組成物および方法

Country Status (15)

Country Link
US (1) US20230151107A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126961A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023526890A (cg-RX-API-DMAC7.html)
KR (1) KR20220165267A (cg-RX-API-DMAC7.html)
CN (1) CN115698071A (cg-RX-API-DMAC7.html)
AU (1) AU2021247258A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018936A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174566A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002684A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014199A2 (cg-RX-API-DMAC7.html)
IL (1) IL296487A (cg-RX-API-DMAC7.html)
MX (1) MX2022012229A (cg-RX-API-DMAC7.html)
TW (1) TW202200202A (cg-RX-API-DMAC7.html)
WO (1) WO2021199006A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202210032B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
IL266087B2 (en) * 2016-10-18 2024-02-01 Biocon Ltd Use of itolizumab to reduce phosphorylation of cd6
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
PT2993186T (pt) * 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
KR20110091780A (ko) * 2008-11-25 2011-08-12 앨더 바이오파마슈티컬즈, 인코포레이티드 악액질, 쇠약, 피로 및/또는 발열을 예방하거나 치료하는 il­6의 길항제
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US10562975B2 (en) * 2016-06-15 2020-02-18 The Regents Of The University Of Michigan CD6 antibody for treatment of T-cell mediated diseases or disorders
WO2019169015A1 (en) * 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
AU2020415307A1 (en) * 2019-12-24 2022-06-09 F. Hoffmann-La Roche Ag Method of treating virus infection using a TLR7 agonist

Similar Documents

Publication Publication Date Title
JP6811723B2 (ja) 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法
Gulati et al. Cytokines and their role in health and disease: a brief overview
KR100912381B1 (ko) 응고 관련 질병을 치료하기 위한 조성물 및 방법
HRP20210876T1 (hr) Anti-tmprss2 antitijela i fragmenti koji vezuju antigen
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
US6846486B1 (en) Method of treating allergy by administering an anti-histamine antibody
KR20070090969A (ko) 톨 유사 수용체 3 길항제, 방법 및 용도
RU2009136677A (ru) Рекомбинантные антитела для лечения респираторно-синцитиальных вирусных инфекций
JP2017113019A5 (cg-RX-API-DMAC7.html)
JP2005533861A5 (cg-RX-API-DMAC7.html)
JP2005523946A5 (cg-RX-API-DMAC7.html)
US20090117105A1 (en) Humanized anti-venezuelan equine encephalitis virus recombinant antibody
JPH04211392A (ja) モノクローナル抗体、抗体特性を有する蛋白質、ハイブリドーマ細胞系及びモノクローナル抗体の作製法
CN115515976A (zh) 冠状病毒抗体
JP2017515473A5 (cg-RX-API-DMAC7.html)
KR20180088442A (ko) 병원내 폐렴의 예방 또는 치료 방법
CN117603358B (zh) 一种广谱新型冠状病毒的双特异性抗体
JP2008545381A5 (cg-RX-API-DMAC7.html)
AU2010264764A1 (en) Pharmaceutical agent
CA2729226C (en) Pharmaceutical compositions of antibodies for diseases caused by viruses
JP2024177399A (ja) 呼吸器疾患の治療のための汎elr+cxcケモカイン抗体
JP2022513438A5 (cg-RX-API-DMAC7.html)
WO2023122786A3 (en) ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
JP6800591B2 (ja) インフルエンザ治療剤
KR101453516B1 (ko) 항-vegf 항체를 포함하는 자가면역질환 예방 및 치료용 조성물